We are pleased to announce that. a comment by our Chairman and CEO, Toshio Miyata (Professor, Tohoku University Graduate School of Medicine), was featured on NHK General TV’s “Ohayo Nippon” program, broadcast on November 15, 2025.
The broadcast focused on the development of Taiwan’s biotechnology industry and related pharmaceutical development efforts through collaboration between Japan and Taiwan.
Through collaborative research with universities and research institutes both in Japan and abroad, we are working to develop pharmaceuticals that can address a wide range of disease areas and healthspan, isuch as cancers and longevity, and cancer. In particular, in Taiwan, we are collaborating with Taipei Medical University (TMU) to promote joint research and development of the PAI-1 inhibitor RS5614 and programmed medical devices using AI (announced on August 30 and November 5, 2024). These efforts aim to promote clinical research and commercialization in Taiwan.
These collaborative research and development efforts are expected to contribute to the advancement of Taiwan’s biotechnology industry and strengthen its international competitiveness.
https://www.web.nhk/tv/an/ohayou/pl/series-tep-QLP4RZ8ZY3/ep/8RG42R2ZJ8?startOffset=1025
Related links
“Announcement of the joint R&D collaboration agreement for artificial intelligence (AI)-based software as a medical device (SaMD) with Taipei Medical University (TMU)-Biotech Co., Ltd.” (Disclosed on August 30, 2024)
https://www.renascience.co.jp/wp-content/uploads/2024/11/24-0830Announcement-of-the-joint-RD-collaboration-agreement-for-artificial-intelligence-AI-based-software-as-a-medical-device-SaMD-.pdf
“Notice of the completion of a joint development agreement with Taipei Medical University (TMU)-Biotech Co., Ltd. (Taipei) for the PAI-1 inhibitor RS5614.” (Disclosed on November 5, 2024)
www.renascience.co.jp/wp-content/uploads/2024/11/Notice-of-the-completion-of-a-joint-development-agreement-with-Taipei-Medical-University-1.pdf